Additionally, there is evidence that potent P2Y12 inhibition may offer benefits in patients with T2DM and complications such as lower extremity arterial disease, in which ticagrelor improves microvascular flow, for example [45]. This evidence concerns the gene P2RY12 and arterial disorder.